>
Boston Scientific logo

BSX PR A - Boston Scientific Share Price

$128.01 9.7  8.2%

Sector
Healthcare
Size
Large Cap
Market Cap £45.22bn
Enterprise Value £50.34bn
Revenue £7.33bn
Position in Universe th / 7000
Bullish
Bearish
Unlock BSX PR A Revenue
Momentum
Relative Strength (%)
1m -2.56%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.53%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
7,477 8,386 9,048 9,823 10,735 9,913 11,751 12,709 +5.8%
-24.3 +57.3 +29.5 +43.6 -14.7 -60.5 +275.2 +16.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, BostonScientific Corporation revenues increased 8% to $2.75B. Netincome applicable to common stockholders increased from$11M to $327M. Revenues reflect Cardiovascular segmentincrease of 10% to $1.13B, MedSurg segment increase of 11%to $860M, United States segment increase of 9% to $1.58B,Asia Pacific segment increase of 16% to $473M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BSX PR A Revenue Unlock BSX PR A Revenue

Net Income

BSX PR A Net Income Unlock BSX PR A Revenue

Normalised EPS

BSX PR A Normalised EPS Unlock BSX PR A Revenue

PE Ratio Range

BSX PR A PE Ratio Range Unlock BSX PR A Revenue

Dividend Yield Range

BSX PR A Dividend Yield Range Unlock BSX PR A Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BSX PR A EPS Forecasts Unlock BSX PR A Revenue
Profile Summary

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated June 22, 1979
Public Since May 19, 1992
No. of Shareholders: 6,943
No. of Employees: 38,000
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange New York Stock Exchange (Dual Listing)
Shares in Issue 1,420,910,855
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BSX PR A Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to BSX PR A
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.